Metabotropic glutamate receptors as drug targets: what's new?

Nicoletti, F. and Bruno, V. and Ngomba, R. T and Gradini, R. and Battaglia, G. (2015) Metabotropic glutamate receptors as drug targets: what's new? Current Opinion in Pharmacology, 20 . pp. 89-94. ISSN 14714892

Documents
Metabototropic.pdf

Request a copy
[img] PDF
Metabototropic.pdf - Whole Document
Restricted to Repository staff only

326kB
Item Type:Article
Item Status:Live Archive

Abstract

The question in the title: 'what's new?' has two facets. First, are 'clinical' expectations met with success? Second, is the number of CNS disorders targeted by mGlu drugs still increasing? The answer to the first question is 'no', because development program with promising drugs in the treatment of schizophrenia, Parkinson's disease, and Fragile X syndrome have been discontinued. Nonetheless, we continue to be optimistic because there is still the concrete hope that some of these drugs are beneficial in targeted subpopulations of patients. The answer to the second question is 'yes', because mGlu ligands are promising targets for 'new' disorders such as type-1 spinocerebellar ataxia and absence epilepsy. In addition, the increasing availability of pharmacological tools may push mGlu7 and mGlu8 receptors into the clinical scenario. After almost 30 years from their discovery, mGlu receptors are still alive. © 2014 Elsevier Ltd.

Keywords:2 amino 3 (3,4 dichlorobenzyloxy) 6 fluorobicyclo3.1.0hexane 2,6 dicarboxylic acid, 4 amino 2 thiabicyclo3.1.0hexane 4,6 dicarboxylic acid 2,2 dioxide, acetylcysteine, amantadine, atypical antipsychotic agent, azd 2066, basimglurant, dipraglurant, ketamine, levacecarnine, mavoglurant, metabotropic receptor, metabotropic receptor 2, metabotropic receptor 3, metabotropic receptor 4, metabotropic receptor 5, metabotropic receptor 7, metabotropic receptor 8, metabotropic receptor antagonist, n methyl dextro aspartic acid receptor, neuroleptic agent, parvalbumin, pomaglumetad methionil, ro 0711401, ro 4419513, ro 4432717, serotonin 2A receptor, unclassified drug, vu 0360172, ligand, metabotropic receptor, absence, antidepressant activity, Article, autism, cannabis addiction, central nervous system disease, cerebellum disease, cocaine dependence, depression, drug dependence, drug efficacy, drug targeting, drug tolerability, dyskinesia, fragile X syndrome, gene, GRM1 gene, GRM2 gene, happy puppet syndrome, human, long term depression, nonhuman, Parkinson disease, pathogenesis, phase 2 clinical trial (topic), protein expression, receptor down regulation, schizophrenia, thalamocortical tract, tobacco dependence, animal, Central Nervous System Diseases, drug design, drug effects, Epilepsy, Absence, metabolism, molecularly targeted therapy, pathophysiology, Spinocerebellar Ataxias, Animals, Humans, Ligands, Molecular Targeted Therapy, Receptors, Metabotropic Glutamate, Spinocerebellar Ataxias, NotOAChecked
Subjects:B Subjects allied to Medicine > B210 Pharmacology
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:22144
Deposited On:04 Feb 2016 12:15

Repository Staff Only: item control page